Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome
Full-Young Chang
Division of Gastroenterology, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan
Search for more papers by this authorChing-Liang Lu
Division of Gastroenterology, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan
Search for more papers by this authorChih-Yen Chen
Division of Gastroenterology, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan
Search for more papers by this authorJiing-Chyuan Luo
Division of Gastroenterology, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan
Search for more papers by this authorFull-Young Chang
Division of Gastroenterology, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan
Search for more papers by this authorChing-Liang Lu
Division of Gastroenterology, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan
Search for more papers by this authorChih-Yen Chen
Division of Gastroenterology, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan
Search for more papers by this authorJiing-Chyuan Luo
Division of Gastroenterology, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan
Search for more papers by this authorAbstract
Background and Aim: Dioctahedral smectite (DS) is natural adsorbent clay useful in treating acute diarrhea. The aim of this study was to determine DS efficacy on patients with diarrhea-predominant irritable bowel syndrome (D-IBS in a phase III-, 8-week-randomized, double-blind, placebo-controlled trial.
Methods: The 104 patients who met the D-IBS Rome II criteria were randomized to receive either DS (n = 52) or placebo (n = 52) treatment for 8 weeks (three sachets daily). The primary efficacy endpoint was the changes of the visual analog scale (VAS) score of IBS overall disorder and pain/discomfort-related symptoms after treatment on days 28 and 56, respectively. Other outcome measures included improvement of bowel movement disorders. The therapeutic global response was assessed by the patients and investigators at each visit, as was drug safety.
Results: Both treatments diminished overall disorder at each visit (P < 0.01), with respect to primary efficacy. This effect was further observed in DS-treated patients on day 56 (P = 0.0167). Placebo had no effect on the VAS score of pain/discomfort at any visit, whereas DS improved this score on days 28 and 56, respectively (P < 0.05). DS and placebo similarly diminished bowel disorders at each visit; however, only DS improved abdominal bloating (P < 0.01). The global therapeutic responses evaluated by the patients and investigators were similarly distributed. The study drug was well tolerated during the 8-week period.
Conclusion: DS seems acceptable to treat D-IBS patients, particularly for pain-related symptoms.
References
- 1 Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108–31.
- 2 Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1337–90.
- 3 Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480–91.
- 4 Lacy BE, Lee RD. Irritable bowel syndrome: a syndrome in evolution. J. Clin. Gastrotenterol. 2005; 39: S230–42.
- 5 Xiong LS, Chen MH, Chen HX, Xu AG, Wang WA, Hu PJ. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Aliment. Pharmacol. Ther. 2004; 190: 1217–14.
- 6 Chang FY, Lu CL. Irritable bowel syndrome in the 21st century: perspectives from Asia or Southeast Asia. J. Gastroenterol. Hepatol 2007; 22: 4–12.
- 7 Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002; 360: 555–64.
- 8 Lu CL, Chen CY, Lang HC et al. Current patterns of irritable bowel syndrome in Taiwan: the Rome II questionnaire on a Chinese population. Aliment. Pharmachol. Ther. 2003; 18: 1159–69.
- 9 Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br. Med. J. 1978; 2: 653–4.
- 10 Lu CL, Chen CY, Chang FY, Lee SD. The characteristics of small bowel motility in irritable bowel syndrome patients and normal humans: an Oriental study. Clin. Sci. 1998; 95: 165–9.
- 11 Sinhamahapatra P, Saha SP, Chowdhury A, Chakrabarti SK, Ghosh A, Maiti B. Visceral afferent hypersensitivity in irritable bowel syndrome-evaluation by cerebral evoked potential after rectal stimulation. Am. J. Gastroenterol. 2001; 96: 2150–7.
- 12 Gupta V, Sheffield D, Verne GN. Evidence for autonomic dysregulation in the irritable bowel syndrome. Dig. Dis. Sci. 2002; 47: 1716–22.
- 13 Lee CT, Chuang TY, Lu CL, Chen CY, Chang FY, Lee SD. Abnormal vagal cholinergic function and psychological behaviors in irritable bowel syndrome patients with predominant bowel symptoms: a hospital-based Oriental Study. Dig. Dis. Sci. 1998; 43: 1794–9.
- 14 Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53: 1096–101.
- 15 Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 1β in recently acquired pot-infectious irritable bowel syndrome. Gut 2003; 52: 523–6.
- 16 Gwee KA, Leong YL, Graham C et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 400–6.
- 17 Camilleri M, Heading RC, Thompson WG. Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment. Pharmacol. Ther. 2002; 16: 1407–30.
- 18 Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001; 48: 272–82.
- 19 Drossman DA. What dose the future hold for irritable bowel syndrome and the functional gastrointestinal disorders? J. Clin. Gastroenterol. 2005; 39: S251–6.
- 20 Lembo TJ, Fink RN. Clinical assessment of irritable bowel syndrome. J. Clin. Gastroenterol. 2002; 35: S31–6.
- 21 Bueno L. Gastrointestinal pharmacology: irritable bowel syndrome. Curr. Opin. Pharmacol. 2005; 5: 583–8.
- 22 Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine. JAMA 1998; 280: 1585–9.
- 23 Bensoussan A. Establishing evidence for Chinese medicine: a case example of irritable bowel syndrome. Chin. Med. J. (Taipei) 2001; 64: 487–92.
- 24 Floch MH. Use of diet and probiotic therapy in the irritable bowel syndrome, analysis of the literature. J. Clin. Gastroenterol. 2005; 39: S243–6.
- 25 Madkour AA, Madina EM, El-Azouni OE, Amer MA, El-Walili TM, Abbass T. Smectite in acute diarrhea in children: a double-blind placebo-controlled trial. J. Paediatr. Gastroenterol. Nutr. 1993; 17: 176–81.
- 26 Legré M, Andreotti D. Double-blind comparative study on dioctahedral smectite and actapulgite in treatment of colonopathies. Gaz. Med. Fr. 1980; 87: 1–3.
- 27 Leber W. A new suspension form of smectite (liquid diasorb) for the treatment of acute diarrhea: a randomized comparative study. Pharmatherapeutica 1988; 5: 256–60.
- 28 Van Maercke Y, Mallend M. Clinical trial to compare the efficacy and tolerance of Smecta (intestinal topic consisting of dioctahedral smectite) and loperamide in the treatment of acute diarrhea in adults. TIJDSCHR Gastroenterology 1987; 17: 367–9.
- 29 Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95: 232–41.
- 30 Pattee PL, Thompson WG. Drug treatment of the irritable bowel syndrome. Drugs 1992; 44: 200–6.
- 31 Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann. Intern. Med. 2000; 133: 136–47.
- 32 Chang L, Toner BB, Fukudo S et al. Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology 2006; 130: 1435–46.
- 33 Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterol. Motil. 2005; 17: 643–53.
- 34 Droy-Lefaix MT, Drouet Y, Schatz B. Sodium glycodeoxycholate and spinability of gastrointestinal mucus. protective effect of smectite. Gastroenterology 1985; 88: 1369A.
- 35 Droy-Lefaix MT, Drouet Y, Geraud G. Protective effect of smectite on gastrointestinal biliary salts rat damage. Gastronterol. Int. 1988; 1 (Suppl. 1): 1076.
- 36 Moré J, Bénazet J, Fioramonti J, Droy-Lefaix MT. Effects of treatment with smectite on gastric and intestinal glycoproteins in the rat: a histochemical study. Histochem. J. 1987; 19: 665–70.
- 37 Leonard AJ, Droy-Lefaix MT, Allen A. Pepsin damage in rat stomach in vivo: effect of smectite and dimethyl prostaglandin E2. Gastroenterology 1993; 104: A132.
- 38 Mahraoui L, Heyman M, Plique O, Droy-Lefaix MT, Desjeux JF. Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-alpha. Gut 1997; 40: 339–43.
- 39 Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804–11.
- 40 Collins SM, Barbara G. East meets west: infection, nerves, and mast cells in irritable bowel syndrome. Gut 2004; 53: 1068–9.
- 41 Opriu AL, Diculescu M, Lov A et al. Enterocyte covering agent versus intestinal motility inhibitor in the irritable bowel. Gut 1996; 39 (Suppl.): A34.
- 42 Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial. Aliment. Pharmacol. Ther. 2005; 21: 435–44.
- 43 Dapoigny M, Giral P, Plique O. Visible abdominal swelling and functional disorders of the intestine (FDI): should medical treatment be given along with dietary advice? Gut 1995; 37: 1366.
- 44 De Sola Pool N, Loehle K, Radzik AJ, Kinsley J. A comparison of nonsystemic and systemic antidiarrheal agents in the treatment of acute non-specific diarrhea in adults. Today's Ther. Trends 1987; 5: 31–8.
- 45 Wingate D, Phillip SF, Lewis SJ et al. Guidelines for adults on self-medication for the treatment of acute diarrhea. Aliment. Pharmacol. Ther. 2001; 15: 773–82.
- 46 Irvine EJ, Whitehead WE, Chey WD et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006; 130: 1538–51.
Citing Literature
